-- Expert-led symposium will explore
key emerging themes in aesthetics, supported by
injection session live from Allergan Aesthetics Center of
Excellence in Italy --
-- New clinical data will be presented to
support evolving Allergan Aesthetics portfolio --
-- 2024 marks 10
years of Allergan Medical Institute (AMI) and a decade of
commitment to science and advanced education --
IRVINE,
Calif., Jan. 25, 2024 /PRNewswire/
-- Allergan Aesthetics, the industry leader in aesthetics
globally, continues to bring best-in-class programming highlighting
Individuality, Innovation, and Integrity at the International
Master Course on Aging Science (IMCAS) World Congress 2024 in
Paris from February 1-3, 2024. Events include
an Allergan Medical Institute (AMI) symposium, live injection
session, Meet the Expert presentations, and an interactive
exhibition booth that aesthetics practitioners can explore.
The congress activities are underpinned by the theme 'True
Originals', highlighting the profound significance and
influence originality plays in aesthetics. Allergan Aesthetics
defines originality through three primary pillars:
- Individuality: Supporting practitioners to deliver a
personalized aesthetic experience through consultation and superior
technique, using a diverse aesthetics portfolio backed by science
and data1-2
- Innovation: Anticipating and serving the aesthetics
needs of patients and providers to create new aesthetic categories
and drive excellence in patient outcomes
- Integrity: Shaping the future of aesthetics through
thoughtful patient engagement, the highest of ethical standards
through training and collaboration maintaining high ethical values,
advanced education, and meaningful partnerships.
IMCAS 2024 AMI Symposium
Ten years ago, Allergan Aesthetics united its long-standing
training and educational programs to launch Allergan Medical
Institute (AMI). 2024 marks a decade
of advancing excellence in clinical practice while empowering
confidence and elevating the craft of medical aesthetics around the
world.
The AMI hosted symposium 'True Originals: Innovation to
Empower Individuality' will spotlight what individuality means
for the industry, and the impact of delivering individualized
aesthetic results through real world examples straight from the
experts. The session will conclude with a live injection session
performed from the Allergan Center of Excellence in Italy.
Date/Time
|
Location
|
Speakers
|
Saturday, February
3,
2024
10:30 AM – 12:30
PM
CET
|
Palais des Congrès
de
Paris, Amphi
Bleu
Level 2
|
•
Dr. Sylwia Lipko-Godlewska
(Poland)
•
Dr. Marva Safa (Switzerland)
•
Dr. Dario Bertossi (Italy)
•
Dr. Alessandro Gritti (Italy)
•
Dr. André Braz (Brazil)
•
and Dr. Patricia Ormiga (Brazil)
|
Beyond the Symposium
La Tribune 2024:
On Friday
February 2, 2004 Micah Bregman, VP Global Strategy and
Pipeline, Allergan Aesthetics, will represent Allergan Aesthetics
at La Tribune 2024. Taking place during the second session of the
day, 4:00 PM – 6:00 PM CET in Amphi Havane, level 3.
New Clinical Data in Posters:
Poster
Topic
|
Presentation
Title
|
Authors
|
HArmonyCa MDR
Interim
Analysis
|
A Prospective,
Open-Label
Post-Marketing Study
of
Safety and
Effectiveness of
Ha/CaHA Filler for
Midface
Soft Tissue
Augmentation:
Interim
Analysis
|
Allesandro Gritti,
Graeme
Kerson, Malka
Salomon,
Andrew Schumacher
|
VFORM Forehead
Contour
|
An Evaluation of
VYC-17.5L
for Forehead
Contouring: A
Prospective,
Open-Label,
Post-Marketing
Study
|
Sofia Ruiz Del
Cueto,
Carola de la Guardia,
Nicola
Kefalas, Graeme
Kerson,
Fernando Urdiales
Galvez,
Alessandro
Gritti
|
Meet the Experts:
Allergan Aesthetics will host a
series of Meet the Experts sessions on the booth
throughout the conference featuring:
Title
|
Provider
|
Treatment choices
guided by Anatomy:
Driving individuality
with the Allergan
Aesthetics
range
|
Dr. Julianna Chieppe
(Brazil)
|
Treating lips across
Ages: Top 10 Tips
|
Dr. Rami Abadi
(Lebanon)
|
Championing Individual
treatment needs in
the Social Media
generation
|
Dr. Katie Beleznay
(Canada)
|
Body: Approaches for
treatment
individualization
|
Dr. Jens Altmann
(Germany)
|
Aesthetic-Ethics:
IMCAS 2024 marks the preview of
the Moving the Needle on Ethics book – a compilation of
thought-provoking pieces on ethical topics associated with
aesthetics, written by aesthetics practitioners from around the
world and intended to continue the conversation on ethics in
aesthetics.
Allergan Aesthetics Booth
The booth (E130, Level 1)
will be a discovery hub for exploring Individuality,
Innovation and Integrity in aesthetics and what it
means to be truly original.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, we
develop, manufacture, and market a portfolio of leading aesthetics
brands and products. Our aesthetics portfolio includes
facial injectables, body contouring, plastics, skin care, and
more. Our goal is to consistently provide our customers with
innovation, education, exceptional service, and a commitment to
excellence, all with a personal touch. For more information, visit
www.allerganaesthetics.com
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
and solutions that solve serious health issues today and address
the medical challenges of tomorrow. We strive to have a remarkable
impact on people's lives across several key therapeutic areas –
immunology, oncology, neuroscience, and eye care – and products and
services in our Allergan Aesthetics portfolio. For more information
about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on
LinkedIn, Facebook, Instagram, X (formerly Twitter), and
YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be
considered, forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "anticipate," "project" and similar expressions and uses
of future or conditional verbs, generally identify forward-looking
statements. AbbVie cautions that these forward-looking statements
are subject to risks and uncertainties that may cause actual
results to differ materially from those expressed or implied in the
forward-looking statements. Such risks and uncertainties include,
but are not limited to, challenges to intellectual property,
competition from other products, difficulties inherent in the
research and development process, adverse litigation or government
action, and changes to laws and regulations applicable to our
industry. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2022 Annual Report on Form 10-K, which has been filed with
the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation, and specifically declines, to release publicly any
revisions to forward-looking statements as a result of subsequent
events or developments, except as required by law.
References:
- Allergan Aesthetics. Data on File. HArmonyCa™ Lidocaine.
Clinical Study Report. July 2022.
REF-99624.
- Ogilvie, et al. J Cosmet Dermatol Surg, 2020: 1065 -1070
View original
content:https://www.prnewswire.com/news-releases/allergan-aesthetics-showcases-commitment-to-individuality-innovation-and-integrity-at-imcas-world-congress-2024-302043796.html
SOURCE AbbVie